No Data
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
Novo-Nordisk A/S stock price has returned to the starting point of the year! Sales of weight loss medication fell short of expectations, scaring off investors.
① The Danish pharmaceutical company novo-nordisk a/s has seen its stock price drop over 40% from its high this year due to increased competition in the weight loss drug market, supply constraints, and financial results that fell short of expectations; ② The financial director of novo-nordisk a/s acknowledged that next year's sales growth could be in the low double digits, significantly lagging behind market expectations; ③ Analysts believe that the current sell-off sentiment on weight loss drugs is excessive, and that the company still possesses high investment value.
More Companies Covering Weight Loss Drugs for Their Employees
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
RFK Jr. Sparks New Worries About Obesity Drugs. Here's What Investors Should Focus on Instead. -- Barrons.com
Novo Nordisk Semaglutide Phase 3 Trial for MASH Meets Primary Endpoints
No Data
No Data
